VX1 vs KardiaAI

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
VX1
by Volta Medical
VS
KardiaAI
by AliveCor

AI Verdict

VX1 is an AI tool specifically designed to assist cardiac electrophysiologists in real-time during atrial fibrillation and atrial tachycardia ablation procedures by identifying dispersed electrograms. In contrast, KardiaAI is an AI software library focused on analyzing ambulatory ECG rhythms to detect various cardiac conditions for diagnostic and monitoring purposes. Therefore, VX1 is suited for procedural guidance in an EP lab, while KardiaAI provides broader ECG analysis for diagnosis and ongoing management.

Choose VX1 if…

Choose VX1 if your primary need is real-time, AI-guided assistance for cardiac electrophysiologists performing atrial fibrillation or atrial tachycardia ablation procedures. This tool is specifically designed to integrate with existing EP lab systems to identify dispersed electrograms during the procedure, aiming to standardize outcomes and reduce inter-operator variability.

View VX1 →

Choose KardiaAI if…

Choose KardiaAI if you require an FDA-cleared AI software library for analyzing ambulatory ECG rhythms to detect a broad range of cardiac conditions, such as AFib, bradycardia, and tachycardia. This solution is ideal for integration into mobile apps, web platforms, or other ECG devices for remote patient monitoring or point-of-care rhythm analysis.

View KardiaAI →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature VX1 KardiaAI
Pricing Contact for pricing Subscription-based for advanced features and services.
Deployment Software integrated with existing electrophysiology (EP) lab mapping and recording systems. Mobile app, cloud-based.
BAA Available Unknown Yes AI-estimated
FDA Status Cleared AI-estimated Cleared AI-estimated
HIPAA Unknown Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

KardiaAI

KardiaAI offers superior general usability with its patient-facing mobile application and simple operation, making medical-grade ECG monitoring accessible to a wider audience, including patients at home. VX1, while effective for its specialized users, is designed for highly trained electrophysiologists in a complex surgical environment, limiting its broad usability.

Clinical Value

VX1

VX1 provides real-time, AI-guided assistance during complex cardiac ablation procedures, directly impacting the success and standardization of an invasive intervention by identifying dispersed electrograms. This direct, intra-procedural impact on a high-stakes procedure suggests a higher immediate clinical impact compared to KardiaAI's broader diagnostic and monitoring capabilities.

Pricing & Value

KardiaAI

KardiaAI clearly wins on pricing transparency and accessibility, offering publicly available subscription models for individual users with clear pricing details. VX1 requires direct contact for pricing, which is typical for enterprise solutions but lacks the immediate transparency and direct-to-consumer affordability of KardiaAI.

Enterprise Readiness

KardiaAI

KardiaAI explicitly states HIPAA compliance and the availability of a Business Associate Agreement (BAA) in its published specifications, which are critical for enterprise adoption in healthcare. While VX1 integrates into specialized EP lab systems, explicit statements regarding BAA and HIPAA compliance are not readily available in the provided information or search results.

Innovation

VX1

VX1 demonstrates a higher degree of innovation by being the first FDA-cleared AI tool in interventional cardiac electrophysiology, providing real-time, AI-guided decision support directly during complex and high-stakes ablation procedures. While KardiaAI's accessible, medical-grade ECG analysis and API library are innovative for remote monitoring, VX1's application in a specialized surgical setting represents a more novel technological advancement.

Support & Docs

KardiaAI

AliveCor, the company behind KardiaAI, offers extensive and publicly accessible support resources, including user manuals, FAQs, and direct contact options for both consumers and developers. While VX1 mentions a user manual, there is less publicly available information about the breadth and accessibility of its support and documentation.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature VX1 KardiaAI
Product Name VX1 KardiaAI
Company Volta Medical AliveCor
Primary Clinical Focus Assists cardiac electrophysiologists in real-time identification of dispersed electrograms during atrial fibrillation and atrial tachycardia ablation procedures. Analyzing ambulatory ECG rhythms, detecting various cardiac conditions like AFib, bradycardia, and tachycardia.
Key AI Functionality AI-guided real-time identification of dispersed electrograms (EGMs); Analyzes 3D anatomical and electrical maps of human atria; Designed to reduce inter-operator variability and standardize outcomes. AI-powered ECG analysis library; Detection of atrial fibrillation, bradycardia, tachycardia, normal sinus rhythm, Sinus Rhythm with Premature Ventricular Contractions (PVCs), Sinus Rhythm with Wide QRS, Sinus Rhythm with Supraventricular Ectopy (SVE); ECG noise filtering.
Specialties Cardiology Cardiology, Emergency Medicine, Internal Medicine

Videos

Demos, reviews, and walkthroughs featuring VX1 and KardiaAI.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

VX1 is an FDA-cleared AI software that assists cardiac electrophysiologists in real-time identification of dispersed electrograms during atrial fibrillation and atrial tachycardia ablation procedures. KardiaAI, also FDA-cleared, is an AI software library for analyzing ambulatory ECG rhythms, detecting various cardiac conditions like AFib, bradycardia, and tachycardia.
VX1 is software integrated with existing electrophysiology (EP) lab mapping and recording systems. KardiaAI is deployed as a Software as a Medical Device (SaMD) and an API library, designed for integration into mobile apps and web platforms.
VX1 focuses on AI-guided real-time identification of dispersed electrograms and provides cycle length estimation from electrograms during ablation procedures. KardiaAI detects atrial fibrillation, bradycardia, tachycardia, normal sinus rhythm, and specific sinus rhythms with PVCs, Wide QRS, or SVE from ambulatory ECGs.
VX1 is primarily designed for Cardiology, specifically assisting electrophysiologists during ablation procedures. KardiaAI is applicable across Cardiology, Emergency Medicine, and Internal Medicine for ECG analysis.
KardiaAI is explicitly stated to be HIPAA compliant and has a Business Associate Agreement (BAA). The provided information for VX1 does not explicitly state whether it is HIPAA compliant or has a BAA.
VX1 is designed for use during in-clinic atrial fibrillation and atrial tachycardia ablation procedures within an EP lab. KardiaAI, as an API library for mobile apps and web platforms analyzing ambulatory ECGs, is suitable for applications involving remote patient monitoring.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform
AISAP Cardio vs Rapid Enterprise Platform
AngioWaveNet vs Rapid Enterprise Platform
CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring VX1 or KardiaAI

Backers

Who funded each tool's parent company.

KardiaAI

AI Tool Finder
AI-powered search. Results may not be comprehensive.